BioMed Research International / 2018 / Article / Tab 2 / Research Article
Lenalidomide and Low Dose Dexamethasone Plus Elotuzumab or Carfilzomib for Relapsed or Refractory Multiple Myeloma: A Comparison of Progression-Free Survival with Reconstructed Individual Participant Data Table 2 Baseline characteristics of patients.
Characteristics Elotuzumab group Carfilzomib group P value(n=321) (n=396) Age - yr median 67 64 NC range 37-88 38-87 Male sex - no. ( ) 192 (60) 215 (54) 0.16 ECOG performance status 0 159 (50) 165 (42) 0.08 1 138 (43) 191 (48) 2 24 (8) 40 (10) Race - no.( ) White 264 (82) 377 (95) < 0.000 Others 57 (18) 19 (5) Time since diagnosis - mo median 41.6 36 NC range 3.6-208.1 4.8-236.4 Disease stage (ISS) no. ( ) I 141 (44) 64 (16) < 0.000 II 102 (32) 99 (25) III 66 (21) 185 (47) unkown 12 (4) 48 (12) Previous therapy regimens median no.(range) 2 (1-4) 2 (1-3) NC regimens no.(%) 1 151 (47) 184 (47) 0.96 2 or more 170 (53) 211 (53)
: statistically significant.
NC: not calculable.